Skip to main content
Lytix Biopharma AS logo

Lytix Biopharma AS — Investor Relations & Filings

Ticker · LYTIX ISIN · NO0010405780 LEI · 549300NXMIMRSBCDZO71 OL Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2026-01-12 Proxy Solicitation & In…
Country NO Norway
Listing OL LYTIX

About Lytix Biopharma AS

https://www.lytixbiopharma.com/

Lytix Biopharma AS is a clinical-stage immuno-oncology company that develops a proprietary platform of oncolytic molecules for cancer treatment. The company's technology is based on molecules designed to selectively target and lyse cancer cell membranes. This process releases a broad spectrum of tumor antigens, which in turn stimulates a patient's immune system to recognize and attack the cancer, effectively turning immunologically "cold" tumors "hot". Its lead drug candidate, ruxotemitide, is being evaluated in clinical trials as a neoadjuvant treatment for various solid tumors, including melanoma and basal cell carcinoma.

Recent filings

Filing Released Lang Actions
Lytix Biopharma AS – Notice of extraordinary general meeting 26 January 2026 - Attachment: Lytix - EGM notice inc appendices 26.01.2026 Final.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is an official 'Notice of Extraordinary General Meeting' (Innkalling til ekstraordinær generalforsamling) for Lytix Biopharma AS. It outlines the agenda, including the election of a chairperson and a proposal for a share capital increase in connection with a subsequent offering. As this document provides the formal materials and agenda for a shareholder meeting, it is classified as Proxy Solicitation & Information Statement (PSI).
2026-01-12 Norwegian
Lytix Biopharma AS – Notice of extraordinary general meeting 26 January 2026
Share Issue/Capital Change Classification · 95% confidence The document is a formal notice announcing an Extraordinary General Meeting (EGM) for Lytix Biopharma AS. It explicitly states that the notice is attached and provides details on the agenda, such as a subsequent share offering, conversion to a public limited company, and board appointments. According to the 'Menu vs Meal' rule, since this is an announcement of a meeting and refers to an attached notice rather than being the full proxy statement or the meeting minutes themselves, it is classified as a Report Publication Announcement (RPA).
2026-01-12 English
Lytix Biopharma AS – Mandatory notification of trade by close associate of primary insider - Attachment: Lytix - Saturn Invest AS - Mandatory Notification of trade by primary insiders and close associ
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR) or a person closely associated with them. It explicitly lists the name of the person (Saturn Invest AS), their relationship to a primary insider (Brynjar Forbergskog), the issuer (Lytix Biopharma AS), and details of the share transaction (subscription and allocation of shares). This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2026-01-09 English
Lytix Biopharma AS – Mandatory notification of trade by close associate of primary insider
Director's Dealing Classification · 100% confidence The document is a mandatory notification of a trade by a close associate of a primary insider (Brynjar Forbergskog) regarding the subscription of shares in a share issue. This falls under the category of Director's Dealing (DIRS), as it reports personal share transactions by individuals closely associated with company insiders, as required by the EU Market Abuse Regulation.
2026-01-09 English
Lytix Biopharma AS: Key information relating to potential subsequent offering
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement regarding a 'subsequent offering' of shares by Lytix Biopharma AS. It details the terms of the offering, including subscription price, record dates, and the number of shares, following a private placement. This falls under the category of capital structure changes and financing activities, specifically related to share issuance and capital raising. Therefore, it is classified as a Capital/Financing Update (CAP).
2026-01-09 English
Lytix Biopharma AS: Private placement successfully completed with oversubscription
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding a completed private placement of shares by Lytix Biopharma AS. It details the number of shares issued, the capital raised, the use of proceeds, and the plan for a subsequent repair offering. This falls squarely under the definition of a share issue and capital change announcement.
2026-01-09 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.